Psychopharmacology is the study of genetic variations to pinpoint more effective personalized treatments for psychiatric disorders. But with clinicians, industry heads, insurance providers, and regulating agencies all weighing in on this practice and forming varying opinions, what’s the best way to move forward? Here to answer that question and others with Dr. Mimi Secor is Dr. James Potash, a Professor of Psychiatry and Behavioral Sciences and Psychiatrist in Chief at the John Hopkins Department of Psychiatry.